Understanding the Breakthrough in Breast Cancer Research from Australia's ONJCRI
A groundbreaking study from the Olivia Newton-John Cancer Research Institute (ONJCRI) has illuminated the intricate world of breast cancer tumor diversity using innovative DNA barcoding techniques. Published on February 11, 2026, in the prestigious journal Molecular Systems Biology, the research titled "Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneity" reveals critical insights into how biopsies—both solid tissue samples and liquid blood tests—represent the complex makeup of breast tumors. Led by Dr. Antonin Serrano during his time at ONJCRI and the Walter and Eliza Hall Institute (WEHI), the work highlights the limitations and potentials of these diagnostic tools, paving the way for more precise monitoring and personalized treatments in breast cancer care.
In Australia, where breast cancer remains the most common cancer among women, with an estimated 20,336 new cases diagnosed in 2025 alone—predominantly 20,129 in females—and around 3,353 deaths, such advancements are vital. The study's findings underscore the role of Australian research institutions in driving global progress, particularly through collaborations between ONJCRI, WEHI, Peter MacCallum Cancer Centre, and universities like La Trobe University and the University of Melbourne.
Intra-Tumoral Heterogeneity: The Hidden Challenge in Breast Cancer
Intra-tumoral heterogeneity (ITH) refers to the diverse subpopulations of cancer cells within a single breast tumor. These clones can differ in aggressiveness, metastatic potential, and response to therapies, driving tumor evolution, recurrence, and resistance. Traditional solid biopsies, obtained via needle from the tumor, often sample only a small portion, potentially missing aggressive clones. Liquid biopsies, which analyze circulating tumor DNA (ctDNA)—fragments of tumor DNA shed into the bloodstream—offer a non-invasive alternative but may not fully capture this diversity.
The ONJCRI team's innovation lies in using DNA barcoding to quantitatively map these clones across entire tumors, biopsies, and blood, providing unprecedented clarity on representation accuracy.
DNA Barcoding: A Powerful Tool for Tracking Cancer Clones Step-by-Step
DNA barcoding, or genetic barcoding, involves using lentiviral vectors—viruses engineered to integrate unique DNA sequences (barcodes) into the genome of individual cancer cells or early clones. Here's how it works step-by-step:
- Step 1: Transduction - Cancer cells (from cell lines or patient-derived xenografts) are infected with a library of lentiviruses, each carrying a distinct 20-30 base pair barcode sequence.
- Step 2: Expansion - Barcoded cells are implanted into mice models, growing into heterogeneous tumors where clones expand independently.
- Step 3: Sampling - Tumors are resected; solid needle biopsies taken; blood plasma collected for cfDNA extraction.
- Step 4: Sequencing - DNA is sequenced using high-throughput methods like next-generation sequencing (NGS) to read barcode frequencies, revealing clonal proportions.
- Step 5: Analysis - Computational tools compare barcode distributions across whole tumor, biopsies, and ctDNA to assess representation fidelity.
This orthogonal approach (combining genetic and sometimes optical barcoding) allows precise lineage tracing, far beyond bulk sequencing.
The Preclinical Models Powering the ONJCRI Discovery
The researchers employed six preclinical breast cancer models: two established cell lines and four patient-derived xenografts (PDXs). PDXs involve implanting fresh human breast tumor tissue directly into immunocompromised mice, preserving patient-specific heterogeneity and genetics more accurately than cell lines. These models mimicked primary tumors and metastases, allowing spatiotemporal tracking over weeks to months.
This rigorous setup enabled side-by-side comparisons, revealing model-specific behaviors crucial for translating findings to human patients.
Key Finding: Higher Clonal Diversity in Tumor Centers Versus Periphery
One striking revelation was spatial heterogeneity within primary tumors. In non-necrotic regions, clonal diversity—measured by barcode richness—was significantly higher in the tumor core compared to the invasive periphery. This suggests that solid needle biopsies, often targeting the tumor edge for accessibility, may underestimate ITH, potentially overlooking dormant or resistant clones sheltered centrally.
"Barcode diversity in the centre of primary tumours was significantly higher than in the periphery, which could have significant implications for the interpretation of solid biopsies," noted Dr. Serrano.
Variable DNA Shedding: Why Liquid Biopsies Miss Clones
Liquid biopsies rely on ctDNA shedding from tumors into circulation. The study found this process highly variable, influenced by:
- Tumor burden (larger tumors shed more);
- Necrosis (dead cells release DNA);
- Intrinsic model differences—even similar-looking tumors shed disparately.
World-first, they detected primary tumor barcodes in plasma, but recovery was low in some highly metastatic models, risking false negatives. This model-specific shedding challenges universal reliance on ctDNA for monitoring.
Combining Solid and Liquid Biopsies for Comprehensive Insights
Neither biopsy type perfectly mirrors whole-tumor composition alone. Solid biopsies capture local snapshots but miss systemic shedding; liquid ones reflect disseminating clones but variably. Integrating both provides a robust ITH assessment, as endorsed by Prof. Delphine Merino: "Our results suggest that both liquid and solid biopsies are, overall, representative of tumour composition, but the results vary between tumours, suggesting that combining both strategies may provide a more accurate representation of the disease."
Clinician Prof. Sarah-Jane Dawson added: "This research will help us understand why some tumours are shedding more DNA than others, and could ultimately lead to a better use of liquid biopsies in the clinic."
Implications for Diagnosis, Treatment, and Precision Oncology in Australia
This work empowers better biopsy-guided decisions. For diagnosis, it cautions against over-relying on peripheral samples; for treatment monitoring, variable ctDNA signals may better predict metastasis or resistance when contextualized. In Australia, where metastatic breast cancer affects ~21,000 individuals, enhancing liquid biopsy accuracy could transform follow-up care post-surgery or chemo.
Funding from NHMRC, National Breast Cancer Foundation, and Love Your Sister highlights national commitment. Ongoing trials like CAPTURE (testing ctDNA for PIK3CA mutations) at Breast Cancer Trials build on this.
Read the full study at Molecular Systems Biology.
Australian Research Landscape: ONJCRI and University Collaborations
ONJCRI, located in Heidelberg, Victoria, is integral to Australia's cancer research ecosystem, partnering closely with La Trobe University's School of Cancer Medicine. This collaboration fosters integrated clinician-researcher teams, accelerating translation. WEHI and Peter MacCallum, affiliated with the University of Melbourne, exemplify higher education's role in biomedical innovation.
For aspiring researchers, opportunities abound in cancer genomics and immunotherapy. Explore research jobs, clinical research positions, or postdoctoral roles to contribute to such advances. Postdocs like Dr. Serrano thrive with advice from our guide on postdoctoral success.
Challenges and Future Directions in Liquid Biopsy Evolution
Challenges include low ctDNA levels in early-stage disease, standardization across labs, and integrating multi-omics (e.g., epigenetics). Future outlooks:
- Refined barcoding for clinical-grade models;
- AI-driven analysis of barcode dynamics;
- Trials combining biopsies for adaptive therapies.
Australia's robust screening via BreastScreen Australia, combined with these insights, promises earlier interventions. Visit Cancer Australia for latest stats.
Photo by Logan Voss on Unsplash
Career Opportunities in Cancer Research and Higher Education
This study exemplifies the impact of multidisciplinary teams in higher education. Whether pursuing a PhD, postdoc, or faculty position, Australia's institutes offer pathways. Check higher ed jobs, university jobs, or tips for research assistants in Australia. For broader advice, see higher ed career advice.
Engage with leaders at ONJCRI via their site.
Conclusion: Transforming Breast Cancer Care Through Rigorous Science
The ONJCRI-led DNA barcoding study marks a milestone in decoding biopsy complexities, promising enhanced diagnostics and therapies. By revealing ITH nuances, it equips clinicians and researchers to combat breast cancer more effectively. Stay informed and explore opportunities at Rate My Professor, Higher Ed Jobs, Career Advice, and University Jobs.